

**REPORTING 2017-Norway**

Date for publication:

|                             | Full name<br><br>(Art. 1.01)   | HCPs: City of Principal Practice<br>HCOs: city where registered<br><br>(Art. 3) | Country of Principal Practice<br><br>Schedule 1) | Principal Practice Address<br><br>(Art. 3) | Unique country identifier OPTIONAL<br><br>(Art. 3) | Donations and Grants to HCOs (Art. 3.01.1.) | Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)                            |                   |                         | Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c) |   | TOTAL OPTIONAL |          |
|-----------------------------|--|---|--|--|--|---|---|-------------------|-------------------------|--|---|----------------|----------|
|                             |  |   |  |  |  |   | Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event | Registration Fees | Travel and Accomodation | Fees   | Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract |                |          |
| HCPs                        | <i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i> |   |  |  |  |   |   |                   |                         |  |   |                |          |
|                             |  |   |  |  |  | N/A   | N/A   | Yearly amount     | Yearly amount           | Yearly amount  | Yearly amount   |                |          |
|                             |  |   |  |  |  |   |   |                   |                         |  |   |                |          |
|                             |  |   |  |  |  |   |   |                   |                         |  |   |                |          |
|                             |  |   |  |  |  |   |   |                   |                         |  |   |                |          |
|                             |  |   |  |  |  |   |   |                   |                         |  |   |                |          |
| HCOs                        | <i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>  |   |  |  |  |   |   |                   |                         |  |   |                |          |
|                             | <b>Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02</b>  |   |  |  |  |   | N/A   | N/A               | Aggregate HCPs          | Aggregate HCPs   | 5000 NOK  | Aggregate HCPs | 5000     |
|                             | <b>Number of Recipients in aggregate disclosure - Art. 3.02</b>  |   |  |  |  |   | N/A   | N/A               | Number                  | Number   | 1   | Number         | Optional |
|                             | <b>% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02</b>  |   |  |  |  |   | N/A   | N/A               | %                       | %  | %   | %              | N/A      |
|                             | <i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i> |   |  |  |  |   |   |                   |                         |  |   |                |          |
|                             |  |   |  |  |  |   |   |                   | Yearly amount           | Yearly amount  | Yearly amount   | Yearly amount  |          |
|                             |  |   |  |  |  |   |   | Yearly amount     | Yearly amount           | Yearly amount  | Yearly amount   |                |          |
| FoU                         | <i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>  |   |  |  |  |   |   |                   |                         |  |   |                |          |
|                             | <b>Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02</b>  |   |  |  |  |   | Aggregate HCOs  | Aggregate HCOs    | Aggregate HCOs          | Aggregate HCOs   | Aggregate HCOs  | Aggregate HCOs | Optional |
|                             | <b>Number of Recipients in aggregate disclosure - Art. 3.02</b>  |   |  |  |  |   | Number  | Number            | Number                  | Number   | Number  | Number         | Optional |
|                             | <b>% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02</b>  |   |  |  |  |   | %   | %                 | %                       | %  | %   | %              | N/A      |
|                             | Not: N/A   |   |  |  |  |   |   |                   |                         |  |   |                |          |
| <b>AGGREGATE DISCLOSURE</b> |  |   |  |  |  |   |   |                   |                         |  |   |                |          |
|                             | Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1  |   |  |  |  |   |   |                   |                         |  | TOTAL AMOUNT  | 275,158.90     |          |

With healthcare professional (HCP) refers to a doctor, dentist, pharmacist, nurse or other staff in the health sector who is entitled to prescribe, purchase, supply, recommend or administer medications, including an employee of pharmaceutical companies whose principal employment is in health and health care. Other employees of pharmaceutical companies or pharmaceutical distributor is not covered by the concept of health professionals.

With healthcare (HCO) means any legal entity which operates health care or research or teaching in this area, or is a professional organization with medical or scientific orientation, with the exception of the association referred to in LER Chapter 3.al.

With the transfer of value for research and development provided for distributions to beneficiaries in planning or execution of (i) non-clinical study (defined in the OECD Principles of Good Laboratory Practice), (ii) clinical trial, or (iii) non-interventional study involving collection of patient data from health professionals or on their behalf.